Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy

Elinzanetant Efficacy:
Elinzanetant, a dual neurokinin-1 and 3 receptor antagonist, has been shown to significantly reduce the frequency and severity of hot flashes (vasomotor symptoms) in women undergoing adjuvant endocrine therapy for breast cancer or at high risk of developing breast cancer14.

Clinical Trials:
The OASIS 4 trial, a phase 3 study, demonstrated that elinzanetant statistically significantly reduced the frequency of moderate to severe vasomotor symptoms from baseline to week 4 and 12 compared to placebo. Improvements in sleep disturbances and menopause-related quality of life were also observed4.

Safety Profile:
The safety profile of elinzanetant was consistent with previously reported results in postmenopausal women with vasomotor symptoms, with common side effects including headache and fatigue24.

Non-Hormonal Option:
Elinzanetant offers a potential non-hormonal solution for managing vasomotor symptoms in breast cancer patients and women at risk of breast cancer, addressing a significant need for alternative treatments45.

Regulatory Status:
The FDA has accepted the New Drug Application (NDA) for elinzanetant for the treatment of vasomotor symptoms in menopause, indicating progress towards potential approval2.

Sources:

1. https://clinicaltrials.bayer.com/study/21656/

2. https://www.contemporaryobgyn.net/view/fda-accepts-elinzanetant-nda-for-vasomotor-symptoms-in-menopause

4. https://www.empr.com/news/elinzanetant-reduces-hot-flashes-caused-by-breast-cancer-therapy/

5. https://endpts.com/bayer-says-elinzanetant-quelled-hot-flashes-in-women-undergoing-cancer-treatment/